Background: Atenolol has been used to treat angina and hypertension, either alone or with other antihypertensives. Despite its usefulness, it shows some side effects such as diarrhea and nausea in some patients. A method for slow release of atenolol in intestine is helpful to prevent such side effects.
Methods: A facile co-precipitation microwave-assisted method was used to fabricate mesoporous hydroxyapatite nanoparticles (mHAp). It was then functionalized to have SO3H groups. The synthesized material was used for storage/slow release study of atenolol.
Results: Atenolol loaded mHAp shows immediate release of atenolol in pH 8, whileafter functionalizing shows up to ca. 30% release at the beginning. In pH 1, 50% of drug was released after 10 h from AT@mHAp and after 18h the drug was almost completely released.The drug release profiles of functionalized HAp at pH value 1 and 8reveals the complete release of atenolol in intestine pH, while no complete release is observed in stomach environment.
Conclusion: The aims of this work were synthesis and characterization of mesoporous HAp through the microwave-assisted co-precipitation method and elucidate the underlying drug release capability of mesoporous HAp nanoparticles. The SO3H group was incorporated into the mesoporous HAp and then used as drug delivery carriers using atenolol as a model drug to investigate their drug storage/release properties in simulated body fluid (SBF). Increasing pH value to 8 causes increase in the drug release.
Keywords: Atenolol, drug release, mesoporous hydroxyapatite nanoparticles, microwave-assisted co-precipitation, MPTS.
Effects of Oral and Non-Insulin Injectable Antidiabetic Treatment in Hypertension: A Systematic Review
Current Pharmaceutical Design Contribution of ALDH2 Polymorphism to Alcoholism-Associated Hypertension
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Under Re-organization) Hemin Treatment Abrogates Monocrotaline-Induced Pulmonary Hypertension
Medicinal Chemistry Hypertension: Quo Vadis?
Current Vascular Pharmacology Patterns of Self-Medication with Medicinal Plants and Related Adverse Events - A South American Survey
Current Drug Safety Ouabain Antagonists as Antihypertensive Agents
Current Pharmaceutical Design The Future of Angiotensin II Inhibition in Cardiovascular Medicine
Current Drug Targets - Cardiovascular & Hematological Disorders The Mineralocorticoid Receptor in Endothelial Physiology and Disease: Novel Concepts in the Understanding of Erectile Dysfunction
Current Pharmaceutical Design Modifying Anti-Inflammatory Effect of Diclofenac with Murraya koenigii
Recent Patents on Inflammation & Allergy Drug Discovery Influence of Lifestyle Measures on Hypertriglyceridaemia
Current Drug Targets Mucopolysaccharidosis Type II (Hunter Syndrome): Clinical Picture and Treatment
Current Pharmaceutical Biotechnology The Molecular Basis of Class Side Effects Due to Treatment with Inhibitors of the VEGF/VEGFR Pathway
Current Clinical Pharmacology Angiotensin Receptor Blockers in Hypertension and Cardiovascular Diseases
Cardiovascular & Hematological Agents in Medicinal Chemistry Angiotensin II Type I Receptor Blocker and Endothelial Function in Humans: Role of Nitric Oxide and Oxidative Stress
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Overcoming Barriers to Evidence-Based Diabetes Care
Current Diabetes Reviews Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan
Current Drug Safety Association between Apolipoproteins AI and B and Ultrasound Indicators of Carotid Atherosclerosis
Current Vascular Pharmacology Impact of Angiotensin Converting Enzyme Inhibitors/Angiotensin Receptors Blockers on Mortality in Acute Heart Failure Patients with Left Ventricular Systolic Dysfunction in the Middle East: Observations from the Gulf Acute Heart Failure Registry (Gulf CARE)
Current Vascular Pharmacology Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Antagonists in Experimental Myocarditis
Current Pharmaceutical Design Stress in Gastrointestinal Tract and Stable Gastric Pentadecapeptide BPC 157. Finally, do we have a Solution?
Current Pharmaceutical Design